References
- 1. Abbas AK, Lichtman AH, Pillai S. Cellular and molecular immunology. 7th. ed. Philadelphia: Elsevier, Saunders; 2012. x, 545 p. p.
- 2. Janeway C. Immunobiology : the immune system in health and disease. 6th ed. New York: Garland Science; 2005. xxiii, 823 p. p.
- 3. Murphy K, Travers P, Walport M, Janeway C. Janeway’s immunobiology. 8th ed. New York: Garland Science; 2012. xix, 868 p. p.
- 4. Hasday JD, Thompson C, Singh IS. Fever, immunity, and molecular adaptations. Comprehensive Physiology. 2014;4(1):109-48.
- 5. Sugimoto Y, Narumiya S. Prostaglandin E receptors. The Journal of biological chemistry. 2007;282(16):11613-7.
- 6. Thelen M, Stein JV. How chemokines invite leukocytes to dance. Nature immunology. 2008;9(9):953-9.10.1038/ni.f.20718711432
- 7. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nature reviews Immunology. 2007;7(6):454-65.10.1038/nri2093
- 8. Malek TR. The biology of interleukin-2. Annual review of immunology. 2008;26:453-79.
- 9. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual review of immunology. 2007;25:821-52.
- 10. Feng P, Jyotaki M, Kim A, Chai J, Simon N, Zhou M, et al. Regulation of bitter taste responses by tumor necrosis factor. Brain Behav Immun. 2015;49:32-42.
- 11. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin- induced TNF-alpha production in humans. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003;17(8):884-6.
- 12. Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651-65.
- 13. Balkwill F. Tumour necrosis factor and cancer. Nature reviews Cancer. 2009;9(5):361-71.10.1038/nrc2628
- 14. Petersdorf RG, Beeson PB. Fever of unexplained origin: report on 100 cases. Medicine. 1961;40:1-30.10.1097/00005792-196102000-00001
- 15. Durack DT, Street AC. Fever of unknown origin-reexamined and redefined. Current clinical topics in infectious diseases. 1991;11:35-51.
- 16. Cunha BA. Fever of unknown origin: focused diagnostic approach based on clinical clues from the history, physical examination, and laboratory tests. Infectious disease clinics of North America. 2007;21(4):1137-87, xi.
- 17. Ergonul O, Willke A, Azap A, Tekeli E. Revised definition of ‘fever of unknown origin’: limitations and opportunities. The Journal of infection. 2005;50(1):1-5.
- 18. Finch RG DG, Čivljak R. Fever of unknown origin. In: Begovac J BD, Lisić M, editor. Infectology. Zagreb: Profil International; 2006. p. 123−7.
- 19. Dinarello CA, Gatti S, Bartfai T. Fever: links with an ancient receptor. Current biology : CB. 1999;9(4):R147-50.10.1016/S0960-9822(99)80085-2
- 20. Conti B, Tabarean I, Andrei C, Bartfai T. Cytokines and fever. Frontiers in bioscience: a journal and virtual library. 2004;9:1433-49.
- 21. Chan-Tack KM CB, Bartlett J, Sanders CV, Talavera F. Fever unknown origin: Medscape from WebMD; 2011 (cited 2012 8 July 2012).
- 22. M. P. Febrilno stanje nepoznatnog uzroka. In: bolesti Kzi, editor. Infektivne bolesti. Beograd: Medicinski fakultet Univerziteta u Beogradu; 2004. p. 387-91.
- 23. Bosnic D, Baresic M, Padjen I, Balenovic A, Zarkovic K, Anic B. Fever of unknown origin: large vessel vasculitis diagnosed by PET/CT. Rheumatology international. 2013;33(9):2417-21.10.1007/s00296-012-2425-1
- 24. Basu S, Ranade R. 18-Fluoro-deoxyglucose-PET/Computed Tomography in Infection and Aseptic Inflammatory Disorders: Value to Patient Management. PET clinics. 2015;10(3):431-9.
- 25. Popovska-Jovičić B, Čanović P, Gajović O, Raković I. and Mijailović Ž. Fever of unknown origin: Most frequent causes in adults patients. Vojnosanit Pregl 2016; 73 (1): 21-25.
- 26. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. British journal of pharmacology. 2013;169(8):1672-92.
- 27. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell death and differentiation. 2003;10(1):45-65.
- 28. Kant S, Swat W, Zhang S, Zhang ZY, Neel BG, Flavell RA, et al. TNF-stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes & development. 2011;25(19):2069-78.
- 29. Raaschou P, Simard JF, Asker Hagelberg C, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. Bmj. 2016;352:i262.
- 30. Sandri MT, Passerini R, Leon ME, Peccatori EA, Zorzino L, Salvatici M, Riggio D, Cassatella C, Cinieri S, and Martinelli G. Procalcitonin as a useful marker of infection in hemato-oncological patients with fever. Anticancer research 2008; 28: 3061-3066.
- 31. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, et al. “HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo”. British Journal of Cancer, 2005; 92 (8): 1430–41. doi:10.1038/sj.bjc.6602487
- 32. Barrie JR, English JC, Muller N: Castleman’s disease of the lung: radiographic, high-resolution CT, and pathologic findings. AJR Am J Roentgenol 1996; 166:1055-1056